<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880125</url>
  </required_header>
  <id_info>
    <org_study_id>YJ4-101</org_study_id>
    <nct_id>NCT01880125</nct_id>
  </id_info>
  <brief_title>Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen Combination</brief_title>
  <official_title>Clinical Trial to Compare the Pharmacokinetics Profile of YJAT Sustained Release Tablet and ULTRACET® Immediate Release Tablet After Oral Administration to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yungjin Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yungjin Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Objective: To evaluate the pharmacokinetic profiles of an SR 75 mg tramadol/650 mg&#xD;
           acetaminophen formulation compared with an immediate release (IR) 37.5 mg tramadol/325&#xD;
           mg acetaminophen formulation after a single dose and at steady state&#xD;
&#xD;
        2. Subjects: Healthy subject&#xD;
&#xD;
        3. Methods: A phase I study to evaluate the pharmacokinetic sustained release and immediate&#xD;
           release treatment profiles at steady state.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was open, randomized, 2-period, 2-treatment multiple-dose crossover study of&#xD;
      immediate release treatment and sustained release treatment was designed to assess the&#xD;
      pharmacokinetics after a 2-day repeated administration in which the steady state was&#xD;
      achieved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the pharmacokinetic profiles of tramadol and acetaminophen at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Bio-equivalence of Cmax at steady state of tramadol and acetaminophen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the pharmacokinetic profiles of tramadol and acetaminophen at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Bio-equivalence of AUC at steady state of tramadol and acetaminophen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Tmax of tramadol and acetaminophen at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Half-life of tramadol and acetaminophen at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Accumulation index of tramadol and acetaminophen at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Cmax of O-desmethyltramadol at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>AUC of O-desmethyltramadol at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Tmax of O-desmethyltramadol at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics profiles of tramadol, acetaminophen and O-desmethyltramadol at steady state</measure>
    <time_frame>0 to 36 hour</time_frame>
    <description>Half-life of O-desmethyltramadol at steady state</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol HCI/Acetaminophen</intervention_name>
    <description>Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>ULTRACET immediate release tablet</other_name>
    <other_name>YJAT sustained release tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between the ages of 20 and 45 years&#xD;
&#xD;
          -  Subjects weighed ≥ 45 kg and were within 20% of their ideal body weight&#xD;
&#xD;
          -  No clinically relevant abnormalities identified by vital sign measurement, 12-lead&#xD;
             electrocardiography and routine laboratory test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity or histories of sensitivity to either tramadol or acetaminophen&#xD;
&#xD;
          -  Evidence or histories of clinically significant renal, digestive, respiratory,&#xD;
             musculoskeletal, endocrine, psychiatric, neurological, hematological or cardiovascular&#xD;
             diseases&#xD;
&#xD;
          -  Taking any prescription or herbal medicines within 2 weeks before the study or any&#xD;
             over-the-counter medication within 1 week before the study&#xD;
&#xD;
          -  Systolic blood pressure (SBP) ≥ 160 mmHg or ≤ 100 mmHg or diastolic blood pressure&#xD;
             (DBP) ≥ 95 mmHg or ≤ 60 mmHg&#xD;
&#xD;
          -  Any surgical or medical conditions that could affect drug absorption&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2013</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tramadol</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Sustained release</keyword>
  <keyword>Immediate release</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

